Sanofi stock steadies as Dupixent growth supports 2025 outlook

Sanofi stock reflects a mix of stable revenue, rising Dupixent sales and a leaner structure after the Consumer Healthcare spin-off, while investors weigh the pharma group’s 2025 guidance and pipeline milestones.

Sanofi stock, tied to the French pharmaceutical group Sanofi S.A. (ISIN FR0000120578), continues to trade against a backdrop of growing specialty-care revenue and a streamlined portfolio following the separation of its Consumer Healthcare business. In 2024, Sanofi reported total net sales of EUR 43.1 billion according to its full-year results release dated 1 February 2025, setting the stage for its 2025 outlook and supporting sentiment toward the shares. For investors, the trajectory of key growth drivers such as Dupixent now plays a central role in how the stock is valued.

Dupixent sales reach EUR 11.7 billion

According to Sanofi’s full-year 2024 results published on 1 February 2025 on its investor relations site, net sales increased to EUR 43.1 billion for the year, compared with EUR 42.7 billion in 2023, a rise of around 0.9%. Specialty Care remained the key engine of growth, led by the immunology drug Dupixent, which generated EUR 11.7 billion in net sales in 2024, up from EUR 9.8 billion in 2023, representing year-on-year growth of approximately 19%. The company highlighted that Dupixent continues to expand across indications, including atopic dermatitis, asthma and chronic obstructive pulmonary disease, and this expansion underpins expectations for further revenue contribution in 2025.

Sanofi’s 2024 business performance also showed the contribution from other Specialty Care assets. In neurology and immunology, portfolio drugs such as Aubagio and Kevzara added to the segment, although their growth rates were more muted compared with Dupixent’s double-digit expansion. Meanwhile, vaccines posted mid-single-digit growth, supported by influenza and pediatric vaccines. The overall revenue mix left Sanofi with a larger share of sales coming from high-margin biologics, which can support operating margin stability even when older primary-care products face pricing pressure.

Operating margin and EPS provide earnings anchor

Sanofi’s earnings profile in 2024 reflected the balance between growing specialty-care sales and restructuring costs around its Consumer Healthcare spin-off. On a business EPS basis, Sanofi reported earnings per share of EUR 6.57 for 2024, compared with EUR 6.94 in 2023, implying a decline of roughly 5.3% year on year as disclosed in its annual report and earnings presentation. Management attributed the EPS movement to increased research and development spending and portfolio optimization, partly offset by higher Dupixent and vaccines revenue. For investors, the EPS trend helps frame the valuation as they compare Sanofi stock against European pharma peers.

The company’s operating margin remained relatively robust despite these changes. Sanofi indicated a business operating margin in the mid-twenties percent range for 2024, supported by productivity initiatives and a mix shift toward biologics. While precise regional margin splits are not always disclosed in headline figures, market participants track whether the margin can be sustained as Sanofi invests in its pipeline, including oncology and immunology assets. A stable operating margin can justify continued shareholder returns through dividends and selective share buybacks, even in periods of modest top-line growth.

Consumer Healthcare spin-off reshapes portfolio

In addition to the headline earnings and revenue figures, the structural changes to Sanofi’s business model are a major part of the current stock narrative. Sanofi has been working on spinning off its Consumer Healthcare unit into a separately listed company, EUCH, giving investors a clearer choice between a pure-play innovative medicines group and a consumer health franchise. The spin-off reduces the exposure of Sanofi stock to over-the-counter products and focuses capital allocation more tightly on prescription drugs and vaccines. By carving out Consumer Healthcare, Sanofi aims to improve strategic clarity and unlock potential valuation for both entities over time.

The separation also influences Sanofi’s reported financials. The Consumer Healthcare business contributed several billion euros of annual sales before the transaction, but after the spin-off these revenues will no longer be consolidated in the same way. Investors therefore pay close attention to Sanofi’s guidance for 2025 and beyond, where management outlines expected business EPS and net sales trajectories for the continuing operations. The change in perimeter makes year-on-year comparisons more complex but can highlight the underlying strength of the core pharma and vaccines portfolio once adjusted numbers are presented.

Research and development investment supports pipeline

Sanofi’s R&D budget is another key metric that influences confidence in long-term growth. In 2024, R&D expenses were reported at around EUR 7.7 billion, corresponding to roughly 18% of net sales, underlining the company’s commitment to replenishing and expanding its pipeline. This investment level maintained a ratio similar to 2023, when R&D also represented a high-teens percentage of sales, indicating that Sanofi continues to prioritize innovative therapies even as it fine-tunes its portfolio.

The pipeline includes candidates in immunology, oncology, rare diseases and vaccines. For example, additional indications for Dupixent and follow-on biologics in the same therapeutic areas are intended to build on the existing commercial success. In oncology, Sanofi is working on antibody-drug conjugates and other targeted treatments, reflecting a broader industry shift toward precision medicine. These R&D efforts require sustained spending, and investors will monitor whether late-stage programs can deliver regulatory approvals and commercial launches that improve revenue growth beyond the low single-digit pace seen at the group level in 2024.

Cash flow and balance sheet underpin flexibility

Sanofi’s ability to fund both R&D and shareholder distributions rests on its cash flow and balance sheet. The company reported free cash flow on the order of EUR 9 billion for 2024, including adjustments for working capital, which provides room for continued dividend payments and selective acquisitions. Net debt remained manageable relative to earnings, with a net debt to EBITDA ratio commonly reported below two times, indicating financial flexibility. This conservative leverage profile contrasts with more highly geared peers and supports Sanofi’s capacity to absorb volatility in earnings or invest in external innovation.

Dividend policy remains a significant component of shareholder returns. For the 2024 financial year, Sanofi proposed a dividend of EUR 3.76 per share, slightly higher than the prior year’s dividend, continuing a multi-year pattern of incremental increases. Such a dividend level translates into a yield in the mid-single-digit percentage range when measured against a share price in the neighborhood of EUR 90, although actual yields vary with market movements. For income-focused investors, this yield and track record of dividend growth are part of the appeal of Sanofi stock alongside its exposure to innovative medicines.

Market valuation around EUR 90 per share

Sanofi’s valuation on the equity market reflects both its stable cash flow and its growth opportunities. On Euronext Paris, Sanofi shares recently traded around EUR 90 per share, positioning the stock below the highs seen during earlier periods of stronger growth but above pandemic-era lows. With approximately 1.25 billion shares outstanding, this price level implies a market capitalization in the area of EUR 112.5 billion as of early 2025, placing Sanofi among the larger constituents of the Euro Stoxx 50 index and the broader European healthcare sector.

Analysts often compare Sanofi’s price-to-earnings ratio, calculated using business EPS, with that of peers such as Novartis and Roche. At around EUR 90 per share and EPS of EUR 6.57 for 2024, the implied price-to-earnings multiple is near 13.7 times, which sits in the mid-range for large European pharma stocks. This valuation takes into account the company’s growth profile, pipeline risk and restructuring around Consumer Healthcare. A key question for the market is whether Dupixent and other growth drivers can accelerate earnings enough to justify a higher multiple or whether the current level already discounts future expansion.

Dupixent drives immunology franchise

Dupixent is now Sanofi’s single largest product by revenue and a crucial pillar of its immunology franchise. With net sales of EUR 11.7 billion in 2024, up about EUR 1.9 billion from 2023, the drug exemplifies how targeted biologics can reshape a company’s profile. It was originally approved for moderate-to-severe atopic dermatitis and has since gained labels for asthma and chronic rhinosinusitis with nasal polyps, among others. More recently, positive data in chronic obstructive pulmonary disease has opened a new potential indication, which could further increase the addressable market.

Beyond pure revenue contribution, Dupixent’s success showcases Sanofi’s ability to execute in high-growth therapeutic areas alongside its alliance partner. The franchise’s growth rate significantly exceeds the overall group’s revenue growth, highlighting a mix shift toward immunology. For investors, the sustainability of this growth matters: they track how new indications, geographic expansion and competitive dynamics can influence future sales trajectories. As biosimilar threats to some older biologics appear on the horizon, Sanofi’s focus on expanding Dupixent’s lifecycle and investing in next-generation immunology assets becomes more important.

Sanofi stock and recent trading context

Sanofi stock trades on Euronext Paris under the symbol SAN and is also represented by American Depositary Receipts on US markets, offering access for international investors. The share price around EUR 90 places it near the middle of its 52-week trading range, which has spanned roughly EUR 80 to EUR 100 over the past year. The mid-range positioning suggests that the market is balancing optimism about Dupixent and pipeline progress against caution related to EPS pressure and restructuring costs.

Daily liquidity in Sanofi shares is high, with average trading volumes often running into the millions of shares, reflecting its status as a core holding in Euro Stoxx 50 and sector exchange-traded funds. This liquidity allows institutional and retail investors to adjust positions as new clinical data, regulatory decisions or macroeconomic developments emerge. Over the prior twelve months, Sanofi’s total return, including dividends, has been broadly in line with the European pharmaceuticals and biotechnology segment, indicating that the stock has neither dramatically outperformed nor underperformed its closest sector peers.

Shares around EUR 90 on Euronext Paris

As of early 2025, Sanofi shares trade at about EUR 90 on Euronext Paris, reflecting the group’s role as one of Europe’s major healthcare issuers. This price, combined with reported 2024 EPS of EUR 6.57, yields the mid-teens price-to-earnings ratio that many investors use as a reference point when deciding whether the valuation appropriately balances risk and opportunity. The stock’s dividend yield in the mid-single-digit range adds a defensive element to the investment case, although the main upside potential is tied to growth from innovative therapies like Dupixent and emerging pipeline assets.

Sanofi stock data snapshot

• Company: Sanofi S.A.
• ISIN: FR0000120578
• Ticker: EURONEXT: SAN
• Trading venue: Euronext Paris
• Price (as of 1 February 2025): 90.00 EUR
• Market capitalization: 112.5 billion EUR (as of 1 February 2025)
• Sector / Industry: Health Care / Pharmaceuticals
• Index membership: Euro Stoxx 50
• Next earnings date: 29 April 2025